VKTX
Viking Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.59B
P/E Ratio
—
EPS
$-4.15
Beta
0.71
52W High
$43.15
52W Low
$22.96
50-Day MA
$32.78
200-Day MA
$32.61
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
-0.03
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -70.00% |
| Return on Assets | -42.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.57 |
| Price-to-Book | 7.15 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -71.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $116.11M |
| Float | $113.28M |
| % Insiders | 2.78% |
| % Institutions | 64.48% |
Historical Volatility
HV 10-Day
49.12%
HV 20-Day
46.63%
HV 30-Day
43.32%
HV 60-Day
50.61%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($92.33 target)
5
Strong Buy12
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026